Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches
Abstract Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer chemotherapies. The mechanisms of MDR and the approaches to test MDR have been discovered, yet not fully understood. This review covers the in vivo and in vitro approaches for the detection of MDR in the la...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2014-06, Vol.347 (2), p.159-166 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 166 |
|---|---|
| container_issue | 2 |
| container_start_page | 159 |
| container_title | Cancer letters |
| container_volume | 347 |
| creator | Wu, Qiong Yang, Zhiping Nie, Yongzhan Shi, Yongquan Fan, Daiming |
| description | Abstract Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer chemotherapies. The mechanisms of MDR and the approaches to test MDR have been discovered, yet not fully understood. This review covers the in vivo and in vitro approaches for the detection of MDR in the laboratory and the mechanisms of MDR in cancers. This study also envisages the future developments toward the clinical and therapeutic applications of MDR in cancer treatment. Future therapeutics for cancer treatment will likely combine the existing therapies with drugs originated from MDR mechanisms such as anti-cancer stem cell drugs, anti-miRNA drugs or anti-epigenetic drugs. The challenges for the clinical detection of MDR will be to find new biomarkers and to determine new evaluation systems before the drug resistance emerges. |
| doi_str_mv | 10.1016/j.canlet.2014.03.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1516722682</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S030438351400158X</els_id><sourcerecordid>3281522431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-65f9983fcd6c9a3fbd0704edd94bf0008bf51ede24e67d33004bc74545e6f203</originalsourceid><addsrcrecordid>eNqFkUtv1TAQRi0EopfCP0AoEhs2CTN-JWGBVFW8pFYg0QU7y7EnXF_yuNgJUv89jm4BqRtW9uLMNzNnGHuOUCGgfn2onJ0GWioOKCsQFaB4wHbY1Lys2wYesh0IkKVohDpjT1I6AICStXrMzrjUqtYaduzL9TosofRx_V5ESiEtdnJUhKlw2ycWbk_jvOwp2iOtS3DpTXFNbm-nkMZU2MkXg-0KezzG2WY2PWWPejskenb3nrOb9-9uLj-WV58_fLq8uCqdQlxKrfq2bUTvvHatFX3noQZJ3rey6_OgTdcrJE9ckq69EACyc7VUUpHuOYhz9uoUm_v-XCktZgzJ0TDYieY1GVSoa851wzP68h56mNc45eE2qkFUIDBT8kS5OKcUqTfHGEYbbw2C2YSbgzkJN5twA8Jk4bnsxV342o3k_xb9MZyBtyeAsoxfgaJJLlBW60Mktxg_h_91uB_ghjAFZ4cfdEvp3y4mcQPm63b07eYoAVA138RvS12nwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1518115031</pqid></control><display><type>article</type><title>Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wu, Qiong ; Yang, Zhiping ; Nie, Yongzhan ; Shi, Yongquan ; Fan, Daiming</creator><creatorcontrib>Wu, Qiong ; Yang, Zhiping ; Nie, Yongzhan ; Shi, Yongquan ; Fan, Daiming</creatorcontrib><description>Abstract Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer chemotherapies. The mechanisms of MDR and the approaches to test MDR have been discovered, yet not fully understood. This review covers the in vivo and in vitro approaches for the detection of MDR in the laboratory and the mechanisms of MDR in cancers. This study also envisages the future developments toward the clinical and therapeutic applications of MDR in cancer treatment. Future therapeutics for cancer treatment will likely combine the existing therapies with drugs originated from MDR mechanisms such as anti-cancer stem cell drugs, anti-miRNA drugs or anti-epigenetic drugs. The challenges for the clinical detection of MDR will be to find new biomarkers and to determine new evaluation systems before the drug resistance emerges.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2014.03.013</identifier><identifier>PMID: 24657660</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Antineoplastic Agents - therapeutic use ; Apoptosis ; Autophagy ; Biomarker ; Breast cancer ; Cancer ; Chemotherapy ; Colleges & universities ; Drug Resistance, Multiple - genetics ; Drug Resistance, Multiple - immunology ; Drug Resistance, Neoplasm - genetics ; Drug Resistance, Neoplasm - immunology ; Epigenesis, Genetic ; Hematology, Oncology and Palliative Medicine ; Humans ; Lab approach ; Mechanism ; Medical research ; MicroRNAs - genetics ; Multi-drug resistance (MDR) ; Ovarian cancer</subject><ispartof>Cancer letters, 2014-06, Vol.347 (2), p.159-166</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2014 Elsevier Ireland Ltd</rights><rights>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jun 1, 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-65f9983fcd6c9a3fbd0704edd94bf0008bf51ede24e67d33004bc74545e6f203</citedby><cites>FETCH-LOGICAL-c511t-65f9983fcd6c9a3fbd0704edd94bf0008bf51ede24e67d33004bc74545e6f203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S030438351400158X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24657660$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Qiong</creatorcontrib><creatorcontrib>Yang, Zhiping</creatorcontrib><creatorcontrib>Nie, Yongzhan</creatorcontrib><creatorcontrib>Shi, Yongquan</creatorcontrib><creatorcontrib>Fan, Daiming</creatorcontrib><title>Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Abstract Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer chemotherapies. The mechanisms of MDR and the approaches to test MDR have been discovered, yet not fully understood. This review covers the in vivo and in vitro approaches for the detection of MDR in the laboratory and the mechanisms of MDR in cancers. This study also envisages the future developments toward the clinical and therapeutic applications of MDR in cancer treatment. Future therapeutics for cancer treatment will likely combine the existing therapies with drugs originated from MDR mechanisms such as anti-cancer stem cell drugs, anti-miRNA drugs or anti-epigenetic drugs. The challenges for the clinical detection of MDR will be to find new biomarkers and to determine new evaluation systems before the drug resistance emerges.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis</subject><subject>Autophagy</subject><subject>Biomarker</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Colleges & universities</subject><subject>Drug Resistance, Multiple - genetics</subject><subject>Drug Resistance, Multiple - immunology</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Drug Resistance, Neoplasm - immunology</subject><subject>Epigenesis, Genetic</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Lab approach</subject><subject>Mechanism</subject><subject>Medical research</subject><subject>MicroRNAs - genetics</subject><subject>Multi-drug resistance (MDR)</subject><subject>Ovarian cancer</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtv1TAQRi0EopfCP0AoEhs2CTN-JWGBVFW8pFYg0QU7y7EnXF_yuNgJUv89jm4BqRtW9uLMNzNnGHuOUCGgfn2onJ0GWioOKCsQFaB4wHbY1Lys2wYesh0IkKVohDpjT1I6AICStXrMzrjUqtYaduzL9TosofRx_V5ESiEtdnJUhKlw2ycWbk_jvOwp2iOtS3DpTXFNbm-nkMZU2MkXg-0KezzG2WY2PWWPejskenb3nrOb9-9uLj-WV58_fLq8uCqdQlxKrfq2bUTvvHatFX3noQZJ3rey6_OgTdcrJE9ckq69EACyc7VUUpHuOYhz9uoUm_v-XCktZgzJ0TDYieY1GVSoa851wzP68h56mNc45eE2qkFUIDBT8kS5OKcUqTfHGEYbbw2C2YSbgzkJN5twA8Jk4bnsxV342o3k_xb9MZyBtyeAsoxfgaJJLlBW60Mktxg_h_91uB_ghjAFZ4cfdEvp3y4mcQPm63b07eYoAVA138RvS12nwg</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Wu, Qiong</creator><creator>Yang, Zhiping</creator><creator>Nie, Yongzhan</creator><creator>Shi, Yongquan</creator><creator>Fan, Daiming</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20140601</creationdate><title>Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches</title><author>Wu, Qiong ; Yang, Zhiping ; Nie, Yongzhan ; Shi, Yongquan ; Fan, Daiming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-65f9983fcd6c9a3fbd0704edd94bf0008bf51ede24e67d33004bc74545e6f203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis</topic><topic>Autophagy</topic><topic>Biomarker</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Colleges & universities</topic><topic>Drug Resistance, Multiple - genetics</topic><topic>Drug Resistance, Multiple - immunology</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Drug Resistance, Neoplasm - immunology</topic><topic>Epigenesis, Genetic</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Lab approach</topic><topic>Mechanism</topic><topic>Medical research</topic><topic>MicroRNAs - genetics</topic><topic>Multi-drug resistance (MDR)</topic><topic>Ovarian cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Qiong</creatorcontrib><creatorcontrib>Yang, Zhiping</creatorcontrib><creatorcontrib>Nie, Yongzhan</creatorcontrib><creatorcontrib>Shi, Yongquan</creatorcontrib><creatorcontrib>Fan, Daiming</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Qiong</au><au>Yang, Zhiping</au><au>Nie, Yongzhan</au><au>Shi, Yongquan</au><au>Fan, Daiming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>347</volume><issue>2</issue><spage>159</spage><epage>166</epage><pages>159-166</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Abstract Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer chemotherapies. The mechanisms of MDR and the approaches to test MDR have been discovered, yet not fully understood. This review covers the in vivo and in vitro approaches for the detection of MDR in the laboratory and the mechanisms of MDR in cancers. This study also envisages the future developments toward the clinical and therapeutic applications of MDR in cancer treatment. Future therapeutics for cancer treatment will likely combine the existing therapies with drugs originated from MDR mechanisms such as anti-cancer stem cell drugs, anti-miRNA drugs or anti-epigenetic drugs. The challenges for the clinical detection of MDR will be to find new biomarkers and to determine new evaluation systems before the drug resistance emerges.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>24657660</pmid><doi>10.1016/j.canlet.2014.03.013</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2014-06, Vol.347 (2), p.159-166 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1516722682 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antineoplastic Agents - therapeutic use Apoptosis Autophagy Biomarker Breast cancer Cancer Chemotherapy Colleges & universities Drug Resistance, Multiple - genetics Drug Resistance, Multiple - immunology Drug Resistance, Neoplasm - genetics Drug Resistance, Neoplasm - immunology Epigenesis, Genetic Hematology, Oncology and Palliative Medicine Humans Lab approach Mechanism Medical research MicroRNAs - genetics Multi-drug resistance (MDR) Ovarian cancer |
| title | Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T06%3A39%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multi-drug%20resistance%20in%20cancer%20chemotherapeutics:%20Mechanisms%20and%20lab%20approaches&rft.jtitle=Cancer%20letters&rft.au=Wu,%20Qiong&rft.date=2014-06-01&rft.volume=347&rft.issue=2&rft.spage=159&rft.epage=166&rft.pages=159-166&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2014.03.013&rft_dat=%3Cproquest_cross%3E3281522431%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1518115031&rft_id=info:pmid/24657660&rft_els_id=S030438351400158X&rfr_iscdi=true |